By Michael Dabaie

 

Sanofi (SNY) said sutimlimab met its primary efficacy endpoint in a Phase 3 trial for patients with cold agglutinin disease.

CAD is a severe and chronic rare blood disorder in which the immune system mistakenly attacks a person's own healthy red blood cells. There are currently no approved treatments, Sanofi said.

A total of 24 patients were enrolled; two withdrew from the study for non-drug related reasons. All 22 patients that completed Part A of the study have enrolled in an ongoing long-term follow-up study.

The primary efficacy outcome was response rate based on a composite of an increase in hemoglobin from baseline or reaching a hemoglobin level at treatment assessment endpoint and the absence of transfusions between weeks 5 to 26.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

November 21, 2019 10:10 ET (15:10 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.